CITY VIEW GREEN HOLDINGS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of City View Green Holdings Inc. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited

As at	Se	D	ecember 31, 2022	
ASSETS				
Current assets				
Cash and cash equivalents	\$	1,369	\$	-
Amounts receivable (note 5)		52,742		95,202
Prepaid expenses		26,037		36,925
Promissory note receivable (note 6)		418,553		392,139
Due from related parties (note 16)		174,310		106,932
Total current assets		673,011		631,198
Non-current assets				
Plant and equipment (note 7)		838,215		1,062,705
Total assets	\$	1,511,226	\$	1,693,903
DEFICIENCY AND LIABILITIES				
Current liabilities			_	
Bank overdraft	\$	-	\$	494
Accounts payable and accrued liabilities (note 9)		2,020,149		1,868,703
Promissory notes payable (note 10)		542,259		293,790
Loans payable (note 11)		824,034		665,730
Due to related parties (note 16)		71,680		65,000
Total current liabilities		3,458,122		2,893,717
Non-current liabilities				
Promissory note payable (note 10)		-		213,315
Total liabilities		3,458,122		3,107,032
Shareholders' deficiency				
Share capital (note 13)		32,206,706		31,831,706
Shares to be issued		157,223		257,223
Contributed surplus (note 14)		8,124,653		8,113,253
Equity portion of convertible loan payable (note 11)		39,500		39,500
Deficit		(42,474,978)		(41,654,811)
Total shareholders' deficiency		(1,946,896)		(1,413,129)
Total shareholders' deficiency and liabilities	\$	1,511,226	\$	1,693,903

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Nature of operations and going concern (note 1)

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) Unaudited

		ree Months Ended otember 30, 2023	ree Months Ended ptember 30, 2022	ne Months Ended otember 30, 2023	ne Months Ended otember 30, 2022
Revenue	\$	-	\$ 63,081	\$ 8,582	\$ 175,281
Expenses					
Depreciation (notes 7 and 8)		74,830	216,200	224,490	639,182
General and administration		111,087	118,881	221,732	232,213
Consulting (note 16)		66,750	149,773	217,572	498,931
Professional fees		25,392	31,472	105,361	154,813
Interest on loans and promissory					
notes payable (notes 10 and 11)		23,183	24,286	67,124	45,014
Accretion (note 11)		-	-	26,334	-
Debt issue costs (notes 11 and 15)		3,500	-	3,500	-
Rent		-	26,951	1,550	20,019
Interest on lease liabilities (note 12)		-	93,248	-	283,493
Supplies		-	69,965	-	198,840
Share-based compensation (note 14)		-	1,100	-	38,900
Advertising and promotion		-	2,000	-	2,000
Total expenses		304,742	733,876	867,663	2,113,405
Net loss before interest and undernoted items		(304,742)	(670,795)	(859,081)	(1,938,124)
Interest income (note 6)		9,226	8,049	26,414	19,506
Gain on debt settlement (note 13)		-	-	12,500	31,545
Net loss and comprehensive loss for the period	\$	(295,516)	\$ (662,746)	\$ (820,167)	\$ (1,887,073)
Basic and diluted net comprehensive					
loss per share (note 17)	\$	(0.00)	\$ (0.00)	\$ (0.00)	\$ (0.01)
Weighted average number of common shares outstanding - basic and diluted	•	46,587,960	 98,966,327	 11,640,463	292,831,540

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency) (Expressed in Canadian Dollars)

Unaudited

	Share	capital						
	Number of shares	Amount	Shares to be issued		Contributed surplus	Equity portion of convertible loan payable		Total
Balance, December 31, 2021	283,412,270	\$ 30,298,577	\$ 351,78	9 \$	8,665,993	\$ -	\$ (39,238,794)	77,565
Units issued for cash	9,600,000	480,000	(275,00	0)	-	-	-	205,000
Fair value of warrants	-	(201,300) -	,	201,300	-	-	-
Shares issued for debt settlement	1,261,784	56,780	-		-	-	-	56,780
Issued on exercise of warrants	26,980,571	1,197,649	-		(792,940)	-	-	404,709
Shares to be issued	-	-	130,43	4	- '	-	-	130,434
Share-based compensation	-	-	_		38,900	-	-	38,900
Net loss and comprehensive loss for the period	-	-	-		-	-	(1,887,073)	(1,887,073)
Balance, September 30, 2022	321,254,625	\$ 31,831,706	\$ 207,22	3 \$	8,113,253	\$ -	\$ (41,125,867)	(973,685)
Balance, December 31, 2022	321,254,625	\$ 31,831,706	\$ 257,22	3 \$	8,113,253	\$ 39,500	\$ (41,654,811)	(1,413,129)
Shares issued for cash	24,833,335	372,500	(100,00	0)	-	-	-	272,500
Shares issued for debt settlement	500,000	2,500	` -	•	-	-	-	2,500
Warrants issued for debt issue costs	-	-	-		11,400	-	-	11,400
Net loss and comprehensive loss								
for the period	-		<u>-</u>			<u>-</u> _	(820,167)	(820,167)
Balance, September 30, 2023	346,587,960	\$ 32,206,706	\$ 157,22	3 \$	8,124,653	\$ 39,500	\$ (42,474,978)	(1,946,896)

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars) Unaudited

	Nine Months Ended			e Months Ended
	September	r 30 ,	Sept	•
	2023			2022
Operating activities				
Net loss for the period	\$ (820,1	67)	\$ ((1,887,073)
Adjustments for:	•	•		,
Depreciation	224,4	90		639,182
Share-based compensation	-			38,900
Accrued interest	40,7	10		25,508
Interest expense on lease liabilities	-			283,493
Debt issue costs	3,5	00		-
Accretion	26,3	34		-
Gain on debt settlement	(12,5	(00		(31,545)
Changes in non-cash working capital items:				
Amounts receivable	42,4	60		(97,958)
Prepaid expenses	10,8	88		(19,997)
Accounts payable and accrued liabilities	174,3	46		655,360
Net cash used in operating activities	(309,9	39)		(394,130)
Investing activities				
Purchase of plant and equipment	-			(168,318)
Net cash used in investing activities	-			(168,318)
Financing activities				
Proceeds from issuance of shares and units, net of share issue costs	272,5	00		205,000
Proceeds from warrants exercised	<u>-</u> ´			404,709
Proceeds from promissory notes payable	-			200,000
Proceeds from loan payable	100,0	00		-
Advances to related parties	(60,6	98)		(20,000)
Shares to be issued	-	•		130,434
Repayment of lease liabilities	-			(398,862)
Net cash provided by financing activities	311,8	02		521,281
Net change in cash and cash equivalents for the period	1,8			(41,167)
Cash and cash equivalents (bank overdraft), beginning of period	•	94)		42,655
Cash and cash equivalents, end of period	\$ 1,3	69	\$	1,488

Supplemental cash flow information (note 18)

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

1. Nature of operations and going concern

City View Green Holdings Inc. ("City View" or the "Company") was incorporated pursuant to the Canada Business Corporations Act on February 5, 2008. The Company continued into British Columbia from the jurisdiction of Canada, under the *British Columbia Business Corporations Act*, on February 18, 2011. On February 27, 2019, the Company completed a reverse take-over business combination with 2590672 Ontario Inc. ("2590672 Ontario") wherein the Company acquired 100% of the issued and outstanding common shares of 2590672 Ontario and began trading on the Canadian Securities Exchange (the "CSE") under the symbol "CVGR". The Company's registered office is located at 1173 Dundas Street East, Suite 132, Toronto, Ontario, M4M 3P1.

These unaudited condensed interim consolidated financial statements reflect the continuation of the financial position, operating results and cash flows of the Company's legal subsidiary, 2590672 Ontario.

The unaudited condensed interim consolidated financial statements have been prepared using accounting policies applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due. As at September 30, 2023, the Company has an accumulated deficit of \$42,474,978 and a working capital deficit of \$2,785,111, and for the year then ended, the Company had a net loss of \$820,167. These conditions raise material uncertainties which cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. While the Company is continuing its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations. The unaudited condensed interim consolidated financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

On April 30, 2021, the Company received a cannabis processing license from Health Canada. The processing license allows the Company to produce cannabis edibles and related products and allows the Company to conduct development activities, including the formulation of proprietary cannabis infused edibles. On April 21, 2022, the Company further received its cannabis research license from Health Canada.

2. Basis of presentation

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of November 29, 2023, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual financial statements as at and for the year ended December 31, 2022. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2023 could result in restatement of these unaudited condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

3. Significant accounting judgments, estimates and assumptions

The preparation of the consolidated financial statements using accounting policies consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. The preparation of the consolidated financial statements also requires management to exercise judgment in the process of applying the accounting policies.

Critical accounting estimates

Share-based compensation – management is required to make a number of estimates when determining the compensation expense resulting from share-based transactions, including the forfeiture rate and expected life of the instruments.

Warrants – management is required to make a number of estimates when measuring the value of warrants including expected life of the instruments.

Plant and equipment and right-of-use assets - management is required to estimate the useful lives and residual value of property, plant and equipment which are included in the consolidated statements of financial position and the related depreciation included in the consolidated statements of loss.

Recoverability of promissory notes receivable – Management's assessment of whether indicator of write off the receivable are present requires judgment based on facts and circumstances at reporting period ends.

Critical judgments in applying accounting policies

Income taxes – measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements.

Going concern – the assessment of the Company's ability to continue as a going concern involves judgment regarding future funding available for its operations and working capital requirements as discussed in note 1.

Impairment assessment of investment in associate – Management's assessment as to whether there is any objective evidence that its net investment in the associate is impaired. Management must determine whether there has been a loss event that has an impact of the estimated future cash flows from the net investment that can be reliably estimated. Objective evidence that the net investment is impaired includes observable data that comes to the attention of the entity.

Impairment of plant and equipment and right-of-use assets - assessing whether indicators of impairment exist at reporting period ends and, if required, determining recoverable amounts including assumptions and inputs thereto.

Intangible assets – The Company applies judgment to assess whether there are any indications that its intangible assets may be impaired. This assessment requires an assessment of external, internal and other indicators at the end of each reporting period.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

4. Capital risk management

The Company manages its capital with the following objectives:

- to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities; and
- to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and financial markets in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, or adjusting spending. The capital structure is reviewed by management and the Board of Directors on an ongoing basis.

The Company considers its capital structure to consist of share capital, shares to be issued, contributed surplus, equity portion of convertible loan payable, and deficit, which at September 30, 2023 totaled a deficiency of \$1,946,896 (December 31, 2022 - deficiency of \$1,413,129). The Company reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. Selected information is provided to the Board of Directors of the Company. The Company is not subject to any capital requirements imposed by a lending institution.

5. Amounts receivable

	Sep	As at September 30, 2023		
Sales tax recoverable (i)	\$	46,151	\$	95,202
Amounts receivable		6,591		-
	\$	52,742	\$	95,202

⁽i) Sales tax receivable is not past due.

6. Promissory note receivable

On March 5, 2019, the Company entered into a loan agreement in the amount of \$200,000 with 11103016 Canada Inc. ("11103016 Canada"). The loan is secured by 11103016 Canada's inventory and equipment, and bears interest rate of Prime Bank Rate plus 5% per annum, calculated monthly not in advance. The loan is repayable on or before March 5, 2020. The Company loaned an additional \$100,000 to 11103016 Canada in August 2019. On March 5, 2020, the Company extended the repayment date of the loan to December 31, 2020. In April 2021, the repayment date was extended to December 31, 2021, and in April 2022, the repayment date was further extended to December 31, 2022.

As at September 30, 2023, the Company was owed \$418,553 (December 31, 2022 - \$392,139) including accrued interest. The Company is currently negotiating the extension of the repayment date with 11103016 Canada.

City View Green Holdings Inc.
Notes to Condensed Interim Consolidated Financial Statements
September 30, 2023 (Expressed in Canadian Dollars) Unaudited

7. Plant and equipment						
• •	Le	easehold				
Cost	imp	rovement	s Ec	quipment		Total
Dalamas Danamhar 24 2004	Φ 4	400 004	Φ 4	400 000	Φ.	0 500 404
Balance, December 31, 2021	\$ 1	,106,281	\$ 1	,402,823	\$	2,509,104
Additions	(4	89,674		93,779	,	183,453
Impairment (i)		,195,955)		-		1,195,955)
Balance, December 31, 2022 and September 30, 2023	\$	-	\$ 1	,496,602	\$	1,496,602
		easehold	_			
Accumulated depreciation	ımp	rovement	s E	quipment		Total
Balance, December 31, 2021	\$	339,560	\$	142,823	\$	482,383
Depreciation for the year	Ψ	235,750	Ψ	291,074	Ψ	526.824
Impairment (i)		(575,310)		-		(575,310)
Balance, December 31, 2022		-		433,897		433,897
Depreciation for the period		-		224,490		224,490
Balance, September 30, 2023	\$	-	\$	658,387	\$	658,387
						_
		easehold				
Carrying value	imp	rovement	s E	quipment		Total
D. I. O. 1000	•		Φ.4	200 705	_	4 000 705
Balance, December 31, 2022	\$	-		,062,705		1,062,705
Balance, September 30, 2023	\$	-	\$	838,215	\$	838,215

(i) During the year ended December 31, 2022, the Company impaired its leasehold improvements as the Company's lease was terminated (see note 12).

8. Right-of-use assets

Cost	Brantford facility
Balance, December 31, 2021 Lease termination (note 12(i))	\$ 3,316,387 (3,316,387)
Balance, December 31, 2022 and September 30, 2023	\$ -
Accumulated depreciation	
Balance, December 31, 2021	\$ 820,077
Depreciation for the year	246,986
Lease termination (note 12(i))	(1,067,063)
Balance, December 31, 2022 and September 30, 2023	\$ -
Carrying value	
Balance, December 31, 2022	\$ -
Balance, September 30, 2023	\$ -

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

9. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to general operating activities.

	Se	As at September 30, 2023		
Accounts payable Accrued liabilities	\$	1,274,258 745,891	\$	1,312,612 556,091
Total accounts payable and accrued liabilities	\$	2,020,149	\$	1,868,703

10. Promissory notes payable

	(Quinsam (i)	Therma (ii)	Other (iii)		Total
Balance, December 31, 2021 Promissory note advanced Interest accrued Repayment	\$	236,246 30,000 27,544	\$ - 200,000 13,315 -	\$ - 100,000 - (100,000)	\$	236,246 330,000 40,859 (100,000)
Balance, December 31, 2022 Interest accrued Balance, September 30, 2023	Φ.	293,790 20,250 314,040	\$ 213,315 14,904 228,219	\$ - -	\$	507,105 35,154 542,259

(i) In August 2021, the Company obtained a \$225,000 secured loan from Quinsam Capital Corporation ("Quinsam"). The loan is repayable by December 31, 2021, bears interest at 10% per annum, and is secured by the Company's assets.

In connection therewith, the Company issued 750,000 warrants to Quinsam. Each warrant is exercisable for one common share of the Company at a price of \$0.15 per share for a period of 2 years. The 750,000 warrants were valued at \$37,300 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 0.47%; dividend yield - 0%; expected stock volatility - 199% and an expected life of 2 years.

In April 2022, the Company extended the repayment date to December 31, 2022. In consideration, the Company agreed to issue 500,000 shares of the Company to Quinsam. As a result, \$15,000 was expensed to debt issue cost.

During the year ended December 31, 2022, the Company obtained an additional \$30,000 loan from Quinsam.

In April 2023, the Company further extended the repayment date to December 31, 2023.

As at September 30, 2023, the Company owed \$314,040 (December 31, 2022 - \$293,790) including accrued interest.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

10. Promissory notes payable (continued)

- (ii) On May 2, 2022, the Company issued a promissory note in the amount of \$200,000 to Therma Bright Inc, ("Therma"), a company with common directors. The note is non-secured, bears interest of 10% per annum and is due on May 2, 2024. As at September 30, 2023, the Company owed \$228,219 (December 31, 2022 \$213,315) including accrued interest.
- (iii) On June 20, 2022, the Company issued a promissory note in the amount of \$100,000 to a third-party lender. The note bore interest at 0.005833% per month, and was due and was repaid on December 31, 2022.

As a security for the obligations, the Company provided a general security agreement to the lender. As additional interest, the Company issued 750,000 warrants of the Company. Each warrant is exercisable for one common share of the Company at a price of \$0.10 per share until June 20, 2024. The 750,000 warrants are valued at \$7,900 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 3.30%; dividend yield - 0%; expected stock volatility - 163% and an expected life of 2 years. As a result, the Company expensed \$7,900 to debt issue cost.

11. Loans payable

	LOC Agreement		CEBA (ii)	Total	
		(•)			- Otal
Balance, December 31, 2021	\$	233,720	\$	40,000	\$ 273,720
Loan advanced		400,000		-	400,000
Equity portion of convertible loan payable		(39,500)		-	(39,500)
Interest accrued		18,344		-	18,344
Accretion		13,166		-	13,166
Balance, December 31, 2022		625,730		40,000	665,730
Loan advanced		100,000		-	100,000
Interest accrued		31,970		-	31,970
Accretion		26,334		-	26,334
Balance, September 30, 2023	\$	784,034	\$	40,000	\$ 824,034

(i) On July 7, 2020, the Company entered into a revolving line of credit agreement (the "LOC Agreement") with a third party lender (the "Lender"), whereby the Company can obtain \$1,500,000 of revolving line of credit financing facility to be used exclusively for the purchase of the Company's business related equipment, deposits for construction work and tenant's improvements on the Company's Brantford facility, or for security, rental payments, taxes and insurance related thereto. The funds advanced under the LOC are non-secured and bore interest at a rate of 10% per annum.

During the year ended December 31, 2021, the LOC Agreement was amended to terminate on April 30, 2022 and bear interest at a rate of 7% per annum effective September 8, 2021.

In September 2022, the LOC Agreement was further amended. Under the terms of the amendment, the Lender may advance up to an additional \$500,000 under the LOC by December 15, 2022, upon certain conditions being met. The funds advanced under the LOC bear interest at a rate of 7% per annum. The Lender has the right at any time until maturity to elect, in its sole discretion, to convert all or any portion of the outstanding amount into fully paid as non-assessable shares at a price of \$0.05 per share. The LOC Agreement was amended to terminate on June 30, 2023. The Company bifurcated \$39,500 to equity and the remaining balance to the carrying value of the loan.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

11. Loans payable (continued)

- (i) (continued) In consideration for lending the funds advanced, the Company issued to the Lender one unit of the Company for each full \$1 advanced. Each unit consisted of one common share of the Company and one common share purchase warrant. Each warrant entitled the Lender to purchase one common share of the Company at the greater of \$0.15 and a 25% premium to the market price of the Company's common shares at the time of issuance and expire in 2 years. In consideration, the Company issued:
 - On July 20, 2020, 250,000 units valued at \$48,250, which consisted of 250,000 common shares valued at \$26,250 and 250,000 warrants valued at \$22,000 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate 0.27%; dividend yield 0%; expected stock volatility 208% and an expected life of 2 years; and
 - On September 16, 2020, 161,688 units valued at \$32,786, which consisted of 161,688 common shares valued at \$17,786 and 161,688 warrants valued at \$15,000 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate 0.26%; dividend yield 0%; expected stock volatility 204% and an expected life of 2 year.

During the during the year ended December 31, 2021, the Company issued 2,755,900 common shares to settle \$220,472 of the LOC.

On June 30, 2023, the LOC Agreement was amended to terminate on December 31, 2023. In connection with the amendment, the Company issued the Lender 3,250,000 share purchase warrants of the Company. The warrants expire on December 31, 2023 and are each exercisable for one common share of the Company at a price of \$0.10 per share. The 3,250,000 warrants were valued at \$3,500 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 4.81%; dividend yield - 0%; expected stock volatility - 352% and an expected life of 4 months.

During the three and nine months ended September 30, 2023, the Company recognized an accretion expense of \$nil and \$26,334, respectively (three and nine months ended September 30, 2022 - \$nil).

(ii) In April 2020, the Company received \$40,000 under the Canada Emergency Business Account (CEBA) program. 25% of the loan is forgivable if repaid by December 31, 2022. The loan accrues no interest until December 31, 2023, and thereafter converts to a 2-year term loan with a 5% annual interest rate. Any portion of the loan is repayable without penalty at any time prior to December 31, 2025.

12. Lease liabilities

	Brantford facility
Balance, December 31, 2021	\$ 2,957,989
Interest expense	283,493
Lease payments	(398,862)
Termination of lease (i)	(2,842,620)
Balance, December 31, 2022 and September 30, 2023	\$ -

(i) On October 3, 2022, the Company terminated its lease agreement with respect to its Brantford facility. As a result, the Company recorded a losson lease termination of \$27,349.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

13. Share capital

(a) Authorized share capital

Unlimited number of common shares, with no par value.

(b) Common shares issued

	Number of common shares	Amount
Balance, December 31, 2021	283,412,270	\$ 30,298,577
Units issued for cash (i)	9,600,000	480,000
Fair value of warrants (i)	-	(201,300)
Common shares issued for debt settlement (ii)	1,261,784	56,780
Issued on exercise of warrants	26,980,571	1,197,649
Balance, September 30, 2022 and December 31, 2022	321,254,625	\$ 31,831,706
Common shares issued for cash (iii)(iv)	24,833,335	372,500
Common shares issued for debt settlement (v)	500,000	2,500
Balance, September 30, 2023	346,587,960	\$ 32,206,706

(i) On March 17, 2022, the Company closed a non-brokered private placement, pursuant to which it issued an aggregate of 9,600,000 units for aggregate gross proceeds of \$480,000. Each unit is comprised of one common share of the Company and one share purchase warrant. Each warrant entitles the holder to purchase one common shares of the Company at a price of \$0.10 per share for a period of 2 years from the closing date, subject to acceleration from and after the date that is fourth months and one day after the closing date, if the closing price of the Company's common shares on the CSE is equal to or exceeds \$0.11 for 5 consecutive trading days, at which time the Company may accelerate the expiry date of the warrants to the date that is 30 following the date on which the Company issues notice to all the warrant holders of the new expiry date.

The 9,600,000 warrants issued were assigned a value of \$201,300 using the Black-Scholes valuation model using the following assumptions: unit price of \$0.05, weighted average risk-free rate of return of 1.89%, expected volatility of 198% based on historical trends, dividend yield of 0%, and expected life of 2 years.

- (ii) On March 17, 2022, the Company also issued 1,261,784 common shares to certain creditors of the Company to settle an aggregate debt of \$88,325. The common shares issued had a deemed price of \$0.045 based on the fair value and as a result, the Company recognized a gain on settlement of debt of \$31,545.
- (iii) On February 17, 2023, the Company closed the first tranche of a non-brokered private placement, pursuant to which it issued 21,666,668 common shares at \$0.015 per share for aggregate gross proceeds of \$325,000. A director of the Company subscribed for 3,333,334 shares for \$50,000.
- (iv) On March 20, 2023, the Company closed the second and final tranche of its non-brokered private placement, pursuant to which it issued 3,166,667 common shares at \$0.015 per share for aggregate gross proceeds of \$47,500. A director of the Company subscribed for 1,500,000 shares for \$22,500.
- (v) On May 1, 2023, the Company issued 500,000 common shares to a creditor of the Company to settle an aggregate debt of \$15,000. The common shares issued had a deemed price of \$0.005 based on the fair value and as a result, the Company recognized a gain on settlement of debt of \$12,500.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

14. Stock options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan may not exceed 15% of the total number of common shares issued and outstanding from time to time. Share options are granted with a maximum term of ten years with vesting terms at the discretion of the Board of Directors.

	Number of stock options	Weighted average exercise price		
Balance, December 31, 2021	34,289,732	\$	0.21	
Granted (i)	500,000		0.10	
Forfeited	(2,780,000)		0.15	
Balance, September 30, 2022 and December 31, 2022	32,009,732	\$	0.21	
Expired	(1,166,400)		0.38	
Balance, September 30, 2023	30,843,332	\$	0.21	

(i) On March 16, 2022, the Company granted 500,000 stock options to a consultant of the Company exercisable at \$0.10 per common share. The options vested immediately and expire in 3 years. The grant date fair value of \$18,500 was assigned to the stock options as estimated by using the Black-Scholes valuation model with the following assumptions: share price of \$0.045, expected dividend yield of 0%, expected volatility of 177%, risk-free rate of return of 1.90%, an expected maturity of 3 years, and forfeiture rate of 0%. For the three and nine months ended September 30, 2023, \$nil (three and nine months ended September 30, 2022 - \$nil and \$18,500, respectively) was expensed to share-based compensation.

The following table reflects the actual stock options issued and outstanding as of September 30, 2023:

Expiry date	Exercise price (\$)	Weighted average remaining contractual life (years)	Number of options outstanding	Number of options vested (exercisable)	
February 18, 2024	0.12	0.39	600,000	600,000	
February 28, 2024	0.75	0.41	600,000	600,000	
February 28, 2024	0.25	0.41	4,560,000	4,560,000	
February 28, 2024	0.75	0.41	3,013,332	3,013,332	
June 3, 2024	0.15	0.68	1,750,000	1,750,000	
July 24, 2024	0.18	0.82	300,000	300,000	
October 4, 2024	0.15	1.01	3,150,000	3,150,000	
December 22, 2024	0.10	1.23	3,250,000	3,250,000	
March 16, 2025	0.10	1.46	500,000	500,000	
September 14, 2025	0.10	1.96	12,920,000	12,920,000	
October 7, 2025	0.10	2.02	200,000	200,000	
	0.21	1.25	30,843,332	30,843,332	

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

15. Warrants

	Number of warrants	Weighted average exercise price		
Balance, December 31, 2021 Issued (i)(ii)(iii) Expired Exercised	59,385,377 12,850,000 (7,111,688) (26,980,571)	\$	0.11 0.10 0.15 0.02	
Balance, September 30, 2022	38,143,118	\$	0.09	
Balance, December 31, 2022 Issued ((iv) and note 10(iii)) Expired	36,041,785 4,000,000 (30,748,214)	\$	0.08 0.10 0.07	
Balance, September 30, 2023	9,293,571	\$	0.12	

- (i) During the nine months ended September 30, 2023, the Company issued an aggregate of nil warrants (nine months ended September 30, 2022 9,600,000 warrants) as a part of its non-brokered private placements. See note 13.
- (ii) During the nine months ended September 30, 2022, the Company issued 750,000 warrants in connection with a secured loan. See note 10(iii).
- (iii) On May 2, 2022, the Company issued 3,250,000 share purchase warrants to a consultant in partial consideration for consulting advisory services. The warrants expire on December 31, 2022 and are each exercisable for one common share of the Company at a price of \$0.10 per share. The fair value of \$19,300 was assigned to the warrants and has been estimated using the Black-Scholes model for pricing warrants under the following assumptions: risk free interest rate 2.66%; dividend yield 0%; expected stock volatility 139% and an expected life of 8 months. For the three and nine months ended September 30, 2023, \$nil (three and nine months ended September 30, 2022 \$19,300) was expensed to share-based compensation. On September 30, 2022, the Company extended the expiry date of these 3,250,000 warrants from December 31, 2022 to March 31, 2023. As a result, during the three and nine months ended September 30, 2023, the Company recognized share-based compensation of \$1,100, as estimated using the Black-Scholes model for option pricing with the assumptions: risk free interest rate 3.76%; dividend yield 0%; expected stock volatility 226% and an expected life 0.5 years.
- (iv) On August 25, 2023, the Company issued 3,250,000 warrants in connection with the amendment of the LOC Agreement. See note 11(i).

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

15. Warrants (continued)

The following table reflects the warrants issued and outstanding as of September 30, 2023:

Expiry date	Exercise price (\$)	Warrants outstanding
=xpy date	μσ (ψ)	
October 8, 2023 (v)	0.15	2,143,571
November 3, 2023 (v)	0.10	550,000
December 31, 2023	0.10	3,250,000
March 17, 2024	0.10	1,600,000
July 30, 2024	0.18	1,000,000
August 12, 2024	0.10	750,000
	0.12	9,293,571

(v) Subsequent to September 30, 2023, 2,693,571 warrants expired unexercised.

16. Related party balances and transactions

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

	Ended September 30,		Ended tember 30,	•		Ended), September 30,	
	2023		2022		2023		2022
Consulting Professional fees	\$ 56,250 10,992	\$	36,250 11,330	\$	168,750 47,521	\$	168,750 33,589
	\$ 67,242	\$	47,580	\$	216,271	\$	202,339

As at September 30, 2023, \$676,440 (December 31, 2022 - \$547,524) included in accounts payable and accrued liabilities was payable to key management personnel.

As at September 30, 2023, the Company advanced \$174,310 (December 31, 2022 - \$92,375) to Budd Hutt Inc., a company in which the Company is a major shareholder of. The advance is non-interest bearing and repayable on demand.

As at September 30, 2023, the Company advanced \$nil to the CEO (December 31, 2022 - \$14,557) for expense reimbursements. The advance is non-interest bearing and repayable on demand.

As at September 30, 2023, the directors of the Company advanced a total of \$71,680 (December 31, 2022 - \$65,000). The advance is non-interest bearing and repayable on demand.

During the nine months ended September 30, 2022, the directors of the Company subscribed for an aggregate of 2,000,000 units for gross proceeds of \$100,000.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2023 (Expressed in Canadian Dollars) Unaudited

17. Loss per share

For the three and nine months ended September 30, 2023, basic and diluted loss per share has been calculated based on the loss attributable to common shares of \$295,516 and \$820,167, respectively (three and nine months ended September 30, 2022 - \$662,746 and \$1,887,073, respectively) and weighted average number of common shares outstanding of 346,587,960 and 341,640,463, respectively (three and nine months ended September 30, 2022 - 298,966,327 and 292,831,540, respectively). Diluted loss per share did not include the effect of convertible debt, stock options, and warrants as they are anti-dilutive.

18. Supplemental cash flow information

Reconciliation of changes in liabilities to cash flows arising from financing activities, including changes arising from both cash and non-cash changes:

	aı	Accounts payable nd accrued liabilities	F	Promissory notes payable	Loans payable	Due to related parties	Total
Balance, December 31, 2022	\$	1,868,703	\$	507,105	\$ 665,730	\$ 65,000	\$ 3,106,538
Changes from financing cash flows				·	•		
Proceeds from loan payable		-		_	100,000	_	100,000
Advances from related parties		-		-	-	6,680	6,680
Total changes from financing							
cash flows		-		-	100,000	6,680	106,680
Other changes							
Accrued interest		-		35,154	31,970	-	67,124
Accretion		-		-	26,334	-	26,334
Changes in non-cash							
working capital items		174,346		-	-	-	174,346
Debt settlement		(15,000)		-	-	-	(15,000)
Warrants issued for debt issue cos	sts	(7,900)		-	-	-	(7,900)
Total other changes		151,446		35,154	58,304	-	244,904
Balance, September 30, 2023	\$	2,020,149	\$	542,259	\$ 824,034	\$ 71,680	\$ 3,458,122